Platelet Rich Plasma (PRP) Therapy in Rancho Cucamonga, CA

What I’d check before adding platelet rich plasma therapy here

Adult obesity in Rancho Cucamonga is 30% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. CDC PLACES (2023, crude) estimates 10.5% of adults in Rancho Cucamonga have diagnosed diabetes — 1.5 points below the U.S. 12% figure. California is outside CDC’s core Diabetes Belt list; use the PLACES city rate anyway. Hawk Medical is the distributor for platelet rich plasma therapy, not a walk-in clinic.

Epidemiology is not a protocol

• CDC PLACES (2023, crude) estimates 10.5% of adults in Rancho Cucamonga have diagnosed diabetes — 1.5 points below the U.S. 12% figure. Adult arthritis here is 21.6% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market platelet rich plasma therapy in Rancho Cucamonga. Mixing lanes is how recoupments start.
• Chronic wounds that stall past 30 days are the typical entry point for cellular/tissue products. CDC diabetes prevalence is the epidemiologic backdrop; JE coverage rules are the billing backdrop. Both have to be true on the same chart.
• California is outside CDC's historical Diabetes Belt core, but the national 12% diabetes figure still applies as a planning baseline until a clinic uses its own payer mix. Clinics asking for regenerative inventory still have to separate HCT/P 361 homologous-use products from unapproved “stem cell” claims (FDA 21 CFR 1271).

Uninsured mix and Medicare CTPs in the same building

JE reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Rancho Cucamonga is 10.5% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic